Capmatinib is a Kinase Inhibitor. The mechanism of action of capmatinib is as a Mesenchymal Epithelial Transition Inhibitor, and Cytochrome P450 1A2 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and Multidrug and Toxin Extrusion Transporter 2 K Inhibitor.
*The following content is generated by AI and is for reference only.
Capmatinib, chemically known as (3R)-N-(4-chloro-6-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-5-fluoro-1-isopropyl-1H-indole-2-carboxamide, is a highly selective and potent inhibitor of the mesenchymal-epithelial transition factor (MET) receptor tyrosine kinase. Its molecular formula is C22H20ClFN4O, and it is registered under the CAS number 1971832-34-6. This small molecule drug functions by competitively binding to the ATP-binding pocket of the MET kinase domain, thereby blocking downstream signaling pathways essential for cell proliferation, survival, and metastasis.
Developed primarily to address resistance mechanisms in non-small cell lung cancer (NSCLC), Capmatinib has emerged as a critical therapeutic option for patients harboring specific MET alterations. These include MET exon 14 skipping mutations, which constitute approximately 3% to 4% of all NSCLC cases, as well as MET gene amplifications. By selectively inhibiting mutant MET while sparing wild-type MET to a significant degree, the drug minimizes off-target toxicity often associated with broader-spectrum kinase inhibitors. Clinical trials have demonstrated its efficacy in both treatment-naïve and previously treated patients, showing high objective response rates and durable disease control.
The pharmacokinetic profile of Capmatinib supports once-daily oral administration, offering convenience for chronic management. It is particularly valuable in scenarios where patients progress on first-line therapies or exhibit specific genetic markers that predict responsiveness. Approved by major regulatory agencies such as the US FDA and EMA, Capmatinib represents a paradigm shift in precision oncology, tailoring treatment to the molecular landscape of individual tumors. While generally well-tolerated, common side effects may include peripheral edema, nausea, and elevated liver enzymes, necessitating routine monitoring during therapy. As research continues, ongoing studies are exploring its potential in combination regimens with other targeted agents or immunotherapies to further enhance clinical outcomes and overcome emerging resistance patterns in advanced malignancies.